Hims & Hers Health (NYSE:HIMS) Price Target Lowered to $30.00 at Bank of America

Hims & Hers Health (NYSE:HIMS) had its price objective decreased by research analysts at Bank of America from $32.00 to $30.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s price objective would indicate a potential upside of 19.86% from the company’s previous close.

Several other research analysts have also commented on HIMS. Canaccord Genuity Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday. UBS Group set a $35.00 price objective on Hims & Hers Health in a report on Tuesday. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday. Evercore set a $24.00 price objective on Hims & Hers Health in a report on Tuesday, February 24th. Finally, TD Cowen cut their price objective on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $29.50.

Hims & Hers Health Trading Down 14.1%

Shares of HIMS opened at $25.03 on Wednesday. The business’s 50-day moving average price is $23.29 and its 200-day moving average price is $29.28. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The stock has a market cap of $5.71 billion, a PE ratio of -278.10, a P/E/G ratio of 3.97 and a beta of 2.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 5.78%. The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the prior year, the company earned $0.20 earnings per share. The company’s quarterly revenue was up 3.8% on a year-over-year basis. On average, equities analysts forecast that Hims & Hers Health will post 0.53 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 97,289 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the sale, the chief operating officer owned 407,282 shares of the company’s stock, valued at $10,055,792.58. This represents a 19.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the sale, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This represents a 38.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 204,857 shares of company stock worth $5,285,706 in the last three months. Corporate insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pathway Capital Management LP purchased a new stake in Hims & Hers Health in the third quarter worth approximately $6,766,000. Steadview Capital Management LLC boosted its stake in shares of Hims & Hers Health by 80.0% during the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after purchasing an additional 311,845 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. BIT Capital GmbH boosted its stake in shares of Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after purchasing an additional 938,728 shares during the period. Finally, State of Michigan Retirement System boosted its stake in shares of Hims & Hers Health by 49.2% during the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after purchasing an additional 678,600 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers raised its FY2026 revenue outlook to $2.8 billion-$3.0 billion, above Wall Street expectations, signaling management expects stronger sales momentum ahead.
• Positive Sentiment: The company said Q2 revenue should come in between $680 million and $700 million, also above consensus, which suggests recovery after the weak first quarter.
• Positive Sentiment: Analyst activity was mixed but still supportive overall, with JPMorgan maintaining an overweight rating and Needham raising its price target to $35, reflecting confidence in longer-term growth.
• Positive Sentiment: Unusual call option buying and articles highlighting strong demand for personalized care and the GLP-1/Novo Nordisk partnership indicate some traders and investors are still betting on a rebound.
• Neutral Sentiment: Recent coverage ahead of earnings focused on expectations, option activity, and the company’s expanded digital health offerings, including labs, menopause, and testosterone care.
• Neutral Sentiment: Hims & Hers also said it plans to move from quarterly to annual shareholder letters, though it will continue earnings calls and releases.
• Negative Sentiment: Q1 results missed estimates on both earnings and revenue, with EPS of -$0.40 versus expectations for a profit and revenue of $608.1 million versus $616.8 million expected, which is the main reason the stock sold off.
• Negative Sentiment: Profitability weakened sharply as the company posted a $92.1 million net loss, and gross margin fell as the GLP-1 weight-loss transition disrupted sales recognition and increased costs.
• Negative Sentiment: The earnings miss prompted several headlines describing the stock as plunging or being hammered, and JPMorgan trimmed its price target from $35 to $33 after the “messy” quarter.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.